Kiniksa Pharmaceuticals
KNSA
108 hedge funds and large institutions have $526M invested in Kiniksa Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 15 closing their positions.
40% more call options, than puts
Call options by funds: $3.06M | Put options by funds: $2.19M
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
19% more capital invested
Capital invested by funds: $442M → $526M (+$83.7M)
4% more funds holding
Funds holding: 104 → 108 (+4)
2.68% more ownership
Funds ownership: 91.42% → 94.09% (+2.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$36M |
| 2 |
State Street
Boston,
Massachusetts
|
+$20.4M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$10.5M |
| 5 |
Goldman Sachs
New York
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$36.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$17.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.23M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.3M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.25M |
KNSA Hedge Fund Activity: Q4 2020 in Review
108 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2020, worth a combined $526M — up 19% from $442M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KNSA positions and 15 closed out — a net gain of 4 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Pictet Asset Management (UK), opening a new position worth an estimated $36M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $36.4M sold.
- 108 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2020, up from 104 in Q3 2020.
- Funds reported $526M of Kiniksa Pharmaceuticals stock for Q4 2020, up 19% quarter-over-quarter.
- 19 funds opened new Kiniksa Pharmaceuticals positions in Q4 2020 and 15 closed out, a net change of +4 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2020 was Pictet Asset Management (UK), an estimated $36M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2020 was Consonance Capital Management, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2020.